Genome Sequencing Testing: Technologies, Standards, Methods, and Applications

Genome sequencing testing is the laboratory process of determining the complete or targeted DNA sequence of humans, animals, plants, and microorganisms to identify genetic variants, characterize microbial strains, and support clinical, agricultural, and industrial decision-making. Accredited third-party laboratories combine validated platforms such as Sanger sequencing, short-read next-generation sequencing (NGS), and long-read single-molecule sequencing with rigorous bioinformatics pipelines compliant with ISO/IEC 17025, ISO 15189, and related national standards. This guide explains the sample requirements, testing items, analytical methods, quality controls, and typical applications of professional genome sequencing testing services.

Technical Overview

Genome sequencing testing refers to the analytical determination of nucleotide order within DNA molecules, ranging from individual gene fragments to entire diploid genomes exceeding six billion base pairs. The testing process decodes the four-base genetic alphabet (A, T, C, G) and converts raw sequencing signals into biologically interpretable information such as single nucleotide variants (SNVs), insertions and deletions (indels), copy number variations (CNVs), and structural variants (SVs). Depending on the objective, testing may target a single amplified fragment, a curated panel of disease-associated genes, the protein-coding exome, or the complete genome of an organism.

Modern genome sequencing testing is built on three technological generations. First-generation Sanger sequencing, based on capillary electrophoresis of chain-terminated fragments, remains the reference method for confirmatory sequencing of short regions. Second-generation short-read platforms use massively parallel sequencing-by-synthesis or ion-semiconductor chemistry to generate hundreds of millions of reads per run with per-base accuracy above 99.9 percent at quality scores of Q30 or higher. Third-generation single-molecule technologies, including real-time consensus sequencing and nanopore-based strand translocation, produce reads tens of kilobases long that resolve repetitive regions, structural rearrangements, and epigenetic modifications inaccessible to short reads.

A complete testing workflow in accredited third-party laboratories typically includes the following stages:

• Sample receipt, accessioning, and chain-of-custody documentation
• Genomic DNA (or RNA) extraction and quantification
• Library preparation, including fragmentation, adapter ligation, and target enrichment where applicable
• Sequencing run execution with real-time instrument quality monitoring
• Bioinformatics analysis: quality filtering, alignment, variant calling, and annotation
• Technical review, interpretation, and issuance of a structured test report

Laboratory competence is governed by internationally recognized frameworks. ISO/IEC 17025 specifies general requirements for the competence of testing laboratories, ISO 15189 addresses quality and competence particular to medical laboratories, ISO 20387 applies to biobanking of biological specimens, and ISO 20395 defines performance criteria for nucleic acid quantification methods. In several jurisdictions, national GB/T standards further specify general technical requirements for next-generation sequencing workflows.

Testing Samples

Human and Animal Biological Samples

Clinical and veterinary genome sequencing testing commonly accepts peripheral whole blood collected in EDTA anticoagulant tubes, buccal (cheek) swabs, saliva stabilizing kits, fresh-frozen tissue, and formalin-fixed paraffin-embedded (FFPE) tissue blocks or sections. Blood is the preferred substrate for germline testing because it yields high-molecular-weight DNA from leukocytes, while FFPE material enables retrospective testing of archived tumor specimens despite its typically fragmented DNA. For cancer applications, matched tumor-normal pairs are recommended to distinguish somatic mutations from inherited germline variants.

Plant Samples

Plant genome projects accept fresh young leaves, surface-sterilized seedlings, seeds, and freeze-dried tissue. Because plant cells contain abundant polysaccharides, polyphenols, and secondary metabolites that inhibit library enzymes, specialized extraction chemistries with CTAB or commercial plant DNA kits are applied. Chloroplast and mitochondrial genomes can often be assembled simultaneously with nuclear data, supporting species identification and phylogenetic studies.

Microbial Isolates

Microbial whole-genome sequencing requires pure, viable cultures submitted as agar slants, plates, glycerol stocks, or extracted DNA of high purity. Bacterial isolates typically require genomic DNA with a concentration above a defined threshold, an A260/280 absorbance ratio near 1.8, and freedom from culture-medium carryover. Fungal, protozoal, and viral isolates follow analogous requirements, with viral workflows often incorporating reverse transcription to convert RNA genomes into sequenceable cDNA.

Environmental and Mixed-Community Samples

Metagenomic testing accepts complex matrices such as water, soil, sludge, food homogenates, swabs from production surfaces, and clinical specimens like bronchoalveolar lavage fluid or cerebrospinal fluid. Direct total-nucleic-acid extraction bypasses cultivation, allowing detection of fastidious or non-culturable organisms and simultaneous profiling of entire microbial communities.

Sample Quality Requirements

Irrespective of matrix, laboratories assess submissions against objective acceptance criteria before analysis:

• Quantity: fluorometric DNA concentration meeting the assay minimum, typically nanogram-to-microgram scale depending on scope
• Purity: A260/280 ratio of 1.8 or above and A260/230 ratio above 1.8, indicating minimal protein and solvent contamination
• Integrity: DNA integrity number (DIN) or gel-based assessment confirming minimal fragmentation, especially for long-read workflows
• Transport and storage: chilled or frozen shipment with temperature monitoring, and short-term storage at 2–8 °C or −20 °C as specified by the method

Testing Items

Genome sequencing testing portfolios are organized by genomic scope and analytical output. The principal testing items are described below.

Whole Genome Sequencing (WGS)

WGS determines the sequence of the entire nuclear genome, delivering comprehensive coverage of coding and non-coding regions. Human WGS is typically performed at 30× to 50× mean depth for germline applications and 80× to 150× or higher for tumor-only somatic analysis. Microbial WGS aims for 100× or greater depth to support closed or draft genome assembly.

Whole Exome Sequencing (WES) and Targeted Gene Panels

WES enriches roughly 1–2 percent of the genome comprising protein-coding exons, where approximately 85 percent of known pathogenic variants reside, achieving 100× or greater mean depth at reduced cost. Targeted panels focus on curated gene sets for specific indications such as hereditary cancer, cardiomyopathy, or pharmacogenomics, providing higher per-base depth (often 500× or more) and faster turnaround.

De Novo Sequencing and Resequencing

De novo sequencing assembles a genome without a reference, applied to novel species, microbial isolates, and breeding lines; hybrid strategies combining long reads for contiguity with short reads for accuracy are standard. Resequencing aligns reads to an existing reference genome to catalogue differences, the dominant mode for human, livestock, and crop studies.

Metagenomic Sequencing

Shotgun metagenomic sequencing characterizes all DNA in a mixed sample, enabling species-level taxonomic profiling, functional gene analysis, antimicrobial resistance gene detection, andvirulence factor identification. 16S/18S rRNA amplicon and internal transcribed spacer (ITS) sequencing provide economical community profiling for bacteria, eukaryotes, and fungi respectively.

Mitochondrial and Organellar Genome Sequencing

Complete mitochondrial genome (mtDNA) testing supports diagnosis of mitochondrial disorders, maternal lineage analysis, and forensic identification. Chloroplast genome sequencing is widely used in plant species barcoding, authenticity verification of herbal materials, and phylogenetic reconstruction.

Variant and Analysis Deliverables

Reportable analytical items typically include:

• Single nucleotide variants (SNVs) and small insertions/deletions (indels)
• Copy number variations (CNVs) and loss of heterozygosity (LOH)
• Structural variants (SVs), translocations, and gene fusions
• Short tandem repeats (STRs) and repeat expansions
• Microsatellite instability (MSI) and tumor mutational burden (TMB)
• Antimicrobial resistance and virulence determinants for microbes
• Gene expression quantification where RNA sequencing is incorporated

Testing Methods

Sanger Sequencing

Sanger sequencing employs fluorescent dye-terminator cycle sequencing followed by capillary electrophoresis, generating reads of approximately 700–1,000 bases with mature accuracy. It is the method of choice for sequencing single genes or PCR amplicons, confirming variants initially detected by NGS, and resolving short ambiguous regions. Its limitation is throughput, as only a limited number of fragments can be analyzed per run.

Short-Read Next-Generation Sequencing

Short-read NGS platforms fragment genomic DNA, ligate indexed adapters, and either amplify fragments on patterned flow-cell surfaces or perform emulsion-based clonal amplification. Sequencing-by-synthesis chemistry images fluorescent incorporation base by base, while ion-semiconductor detection registers pH changes from nucleotide incorporation. Paired-end reads of 100–300 bases are routine, and sample indexing permits multiplexing of dozens to thousands of libraries per run. Key run metrics include percent of bases at Q30 or above, mean target coverage, coverage uniformity, on-target rate, and duplicate rate.

Long-Read Single-Molecule Sequencing

Real-time single-molecule consensus sequencing monitors polymerase activity on individual DNA molecules, generating highly accurate long reads (HiFi) of 15–25 kilobases. Nanopore sequencing measures ionic-current changes as native DNA translocates through protein pores, producing ultra-long reads exceeding 100 kilobases and enabling direct detection of base modifications such as methylation. Long reads resolve complex structural variants, tandem repeat expansions, highly homologous gene clusters, and full microbial plasmids, and they underpin telomere-to-telomere assembly projects.

Bioinformatics Analysis

Standard analysis pipelines proceed through demultiplexing, base calling, adapter and quality trimming, read-level quality control, alignment to a reference genome or de novo assembly, duplicate marking, base-quality recalibration, variant calling, joint genotyping for cohorts, and annotation against reference databases such as dbSNP, ClinVar, COSMIC, gnomAD, and resistance-gene repositories. Clinical interpretation applies classification criteria that assign variants to pathogenic, likely pathogenic, uncertain significance, likely benign, or benign categories, with findings reviewed by qualified analysts before release.

Quality Control and Method Validation

Accredited laboratories validate sequencing workflows for analytical sensitivity, specificity, accuracy, precision, limit of detection, and reportable range, using certified reference materials where available under ISO 17034. Routine quality assurance includes extraction and library controls, positive reference samples, no-template controls to monitor contamination, periodic calibration of pipetting and thermal systems, participation in external proficiency testing schemes, and periodic review of run-level performance against predefined acceptance thresholds. Sequencing data integrity is protected through controlled access, audit trails, and defined retention periods.

Applications

Clinical Diagnostics and Precision Medicine

Genome sequencing testing underpins the diagnosis of rare Mendelian disorders, rapid neonatal intensive care evaluation, carrier screening, preimplantation and non-invasive prenatal testing, hereditary cancer risk assessment, and comprehensive tumor profiling that guides targeted therapy, immunotherapy selection, and clinical trial enrollment. Pharmacogenomic sequencing predicts drug-metabolizing phenotypes to individualize dosing.

Infectious Disease and Public Health

Microbial WGS and metagenomic sequencing identify pathogens directly from clinical specimens, characterize antimicrobial resistance profiles, support hospital outbreak investigations through strain relatedness analysis, and enable genomic epidemiology of epidemic and pandemic viruses. Public health agencies integrate these data into surveillance programs.

Agriculture, Livestock, and Breeding

Genomic selection uses genome-wide marker data to predict breeding values for yield, disease resistance, and quality traits in crops and livestock. Sequencing verifies cultivar identity and purity, maps agronomic loci, characterizes germplasm diversity, and detects transgenic or gene-edited events in support of seed certification and regulatory compliance.

Food Safety and Industrial Biotechnology

Food producers apply strain-level sequencing to trace contamination sources in processing environments, monitor starter and probiotic cultures, screen for spoilage organisms, and verify species authenticity of ingredients. Industrial biotechnology uses genome data to characterize production strains, document genetic stability across passages, and support intellectual property filings.

Environmental Monitoring and Biodiversity Research

Environmental DNA (eDNA) metagenomic testing profiles biodiversity from water, soil, and air samples, assesses ecosystem health, detects endangered or invasive species, and monitors bioremediation microbial communities at contaminated sites.

Forensic and Identity Applications

STR sequencing, mitochondrial genome analysis, and SNP genotyping support human identification, kinship determination, and ancestry inference, while microbial genotyping assists source attribution in forensic investigations.

FAQ

What is the difference between whole genome sequencing and whole exome sequencing?

Whole genome sequencing covers both coding and non-coding regions of the entire genome at moderate depth, capturing structural and regulatory variants that exome testing may miss. Whole exome sequencing enriches only the protein-coding exons at higher per-base depth and lower cost, making it an efficient first-line test for suspected monogenic disorders.

How accurate is genome sequencing testing?

Short-read platforms routinely achieve per-base accuracy above 99.9 percent (Q30 or higher), and high-fidelity long-read consensus reaches comparable accuracy. Clinical sensitivity and specificity for variant classes are established during method validation, and clinically significant findings are typically confirmed by an orthogonal technology such as Sanger sequencing.

What is the typical turnaround time?

Single-gene Sanger testing and targeted panels are often completed within five to ten working days. Whole exome and whole genome testing generally require two to six weeks depending on the depth of analysis and interpretation, while rapid clinical genome protocols can deliver preliminary results within days for urgent cases.

Can degraded FFPE samples be sequenced?

Yes. FFPE-derived DNA is fragmented, so laboratories use short-insert libraries and short-read chemistry optimized for degraded input. Coverage and variant detection may be slightly reduced compared with fresh tissue, and laboratories apply specialized bioinformatics filters to control formalin-induced artifacts.

Which standards govern genome sequencing testing quality?

Testing laboratories operate under ISO/IEC 17025 for general competence, ISO 15189 for medical laboratories, ISO 20387 for biobanking, and ISO 20395 for nucleic acid quantification performance, supplemented by national GB/T and EN standards where applicable. Compliance is verified through accreditation assessments and proficiency testing participation.

How is genetic data confidentiality protected?

Accredited laboratories implement data security controls including role-based access, encrypted storage and transfer, de-identification of sample identifiers, audit logging, and defined data retention and destruction policies consistent with applicable privacy regulations and client agreements.

Is genome sequencing testing suitable for unknown pathogens?

Yes. Metagenomic next-generation sequencing does not require prior knowledge of the agent and can detect bacteria, viruses, fungi, and parasites directly from clinical or environmental specimens, making it valuable in culture-negative infections and unexplained outbreaks.